Glucose Viaflo Baxter Médico Farmacêutica (Glucose Monohydrate)

Glucose Viaflo is indicated for several clinical situations where intravenous carbohydrate delivery is required in acute care.

• Treatment of acute hypoglycemia in patients unable to take oral glucose.
• Component of standard parenteral nutrition regimens to meet daily caloric needs.
• Fluid and electrolyte replacement when combined with appropriate electrolyte solutions.
• Dilution medium for intravenous drug admixtures that require a carbohydrate base for stability.
• Support during peri‑operative fasting to maintain stable plasma glucose levels.
• Emergency management of insulin‑induced hypoglycemia during cardiac arrest resuscitation protocols.

Adverse reactions to intravenous glucose solutions are generally related to the osmotic load and the carbohydrate content.

Common

• Transient hyperglycemia when administered to patients with normal glucose regulation.
• Local irritation or pain at the infusion site.
• Mild electrolyte shifts, particularly sodium and potassium, due to dilution.
• Mild nausea or vomiting when infused rapidly.
• Headache related to rapid changes in plasma osmolality.
• Transient increase in serum lactate levels.

Serious

• Severe hyperglycemia leading to osmotic diuresis.
• Fluid overload in patients with compromised cardiac or renal function.
• Allergic or anaphylactoid reactions, although rare.
• Development of hyperosmolar hyperglycemic state in susceptible individuals.
• Severe electrolyte imbalance such as hypernatremia or hypokalemia.
• Severe hyperglycemia leading to osmotic diuresis.

When prescribing Glucose Viaflo, clinicians should evaluate patient-specific factors to minimize risks associated with intravenous carbohydrate administration.

• Assess baseline blood glucose and adjust infusion rate in diabetic or hypoglycemic patients.
• Monitor fluid balance and avoid excessive volumes in patients with heart failure or renal impairment.
• Use compatible IV sets and avoid mixing with calcium‑containing solutions that may precipitate.
• Check serum electrolytes before and during therapy, especially sodium, potassium, and magnesium.
• Consider the osmolarity of the solution; dilute appropriately for peripheral administration.
• Evaluate for a history of hypersensitivity to glucose preparations.
• Avoid rapid bolus administration unless clinically indicated.

Glucose Viaflo may interact with other intravenous agents or affect the pharmacodynamics of certain medications.

Avoid

• Co‑administration with high‑dose insulin infusions without glucose monitoring.
• Mixing with calcium or phosphate solutions that can cause precipitation.
• Simultaneous infusion of hypertonic dextrose solutions exceeding recommended osmolarity.
• Concurrent infusion with potassium chloride solutions may increase risk of hyperkalemia.

Use with caution

• Concurrent use of diuretics that may exacerbate electrolyte shifts.
• Administration in patients receiving beta‑blockers, as hypoglycemia signs may be masked.
• Overlap with total parenteral nutrition formulations; adjust carbohydrate content to avoid excess calories.
• Patients on corticosteroid therapy may experience altered glucose metabolism; monitor levels closely.